Publikation: rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?
Lade...
Dateien
Zu diesem Dokument gibt es keine Dateien.
Datum
2002
Autor:innen
Liebau, Christian
Merk, Harry
Roesel, Christian
Schmidt, Sebastian
Prisack, Johannes Bernd
Bojar, Hans
Baltzer, Axel W. A.
Herausgeber:innen
ISSN der Zeitschrift
Electronic ISSN
ISBN
Bibliografische Daten
Verlag
Schriftenreihe
Auflagebezeichnung
Internationale Patentnummer
Angaben zur Forschungsförderung
Projekt
Open Access-Veröffentlichung
Sammlungen
Core Facility der Universität Konstanz
Titel in einer weiteren Sprache
Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published
Erschienen in
Anticancer Research. 2002, 22(5), pp. 2559-2565. ISSN 0250-7005. eISSN 1791-7530
Zusammenfassung
Gene therapy is a promising new method to treat tumors locally. Immuno-therapy for treatment of osteosarcomas is one option for hopefully improving the survival rate of patients with this tumor. Transduction of OS cells with the pCMV-IL-12neo plasmid induced a significant increase in IFN-gamma expression by mononuclear cells. This is known to induce antitumor effects mediated by the immune system. In combination with an administration of rIL-18, the IFN-gamma increase was multiplied in a dose-dependent manner. This study demonstrated that osteosarcoma cells can be targeted effectively in vitro by plasmids encoding the IL-12 gene. Considering the synergistic pathways it is reasonable to combine a local, gene transfer based on IL-12 with a rIL-18 administration to trigger the potentially promising immuno-effects for adjuvant treatment of osteosarcomas.
Zusammenfassung in einer weiteren Sprache
Fachgebiet (DDC)
570 Biowissenschaften, Biologie
Schlagwörter
Konferenz
Rezension
undefined / . - undefined, undefined
Zitieren
ISO 690
LIEBAU, Christian, Harry MERK, Christian ROESEL, Sebastian SCHMIDT, Christiaan KARREMAN, Johannes Bernd PRISACK, Hans BOJAR, Axel W. A. BALTZER, 2002. rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?. In: Anticancer Research. 2002, 22(5), pp. 2559-2565. ISSN 0250-7005. eISSN 1791-7530BibTex
@article{Liebau2002rIL18-38814,
year={2002},
title={rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?},
number={5},
volume={22},
issn={0250-7005},
journal={Anticancer Research},
pages={2559--2565},
author={Liebau, Christian and Merk, Harry and Roesel, Christian and Schmidt, Sebastian and Karreman, Christiaan and Prisack, Johannes Bernd and Bojar, Hans and Baltzer, Axel W. A.}
}RDF
<rdf:RDF
xmlns:dcterms="http://purl.org/dc/terms/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:bibo="http://purl.org/ontology/bibo/"
xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
xmlns:foaf="http://xmlns.com/foaf/0.1/"
xmlns:void="http://rdfs.org/ns/void#"
xmlns:xsd="http://www.w3.org/2001/XMLSchema#" >
<rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/38814">
<bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/38814"/>
<dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dc:date>
<dcterms:title>rIL-18 triggered gene therapy based on a transduction with the IL-12 plasmid : a new option as immuno-therapy for osteosarcoma?</dcterms:title>
<dc:contributor>Roesel, Christian</dc:contributor>
<dc:contributor>Merk, Harry</dc:contributor>
<dc:contributor>Schmidt, Sebastian</dc:contributor>
<dc:creator>Schmidt, Sebastian</dc:creator>
<dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<foaf:homepage rdf:resource="http://localhost:8080/"/>
<dc:creator>Liebau, Christian</dc:creator>
<dc:creator>Bojar, Hans</dc:creator>
<void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
<dcterms:issued>2002</dcterms:issued>
<dc:language>eng</dc:language>
<dc:creator>Karreman, Christiaan</dc:creator>
<dc:contributor>Liebau, Christian</dc:contributor>
<dc:contributor>Bojar, Hans</dc:contributor>
<dc:contributor>Karreman, Christiaan</dc:contributor>
<dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2017-05-09T11:11:11Z</dcterms:available>
<dc:creator>Baltzer, Axel W. A.</dc:creator>
<dc:contributor>Prisack, Johannes Bernd</dc:contributor>
<dc:creator>Roesel, Christian</dc:creator>
<dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
<dc:contributor>Baltzer, Axel W. A.</dc:contributor>
<dcterms:abstract xml:lang="eng">Gene therapy is a promising new method to treat tumors locally. Immuno-therapy for treatment of osteosarcomas is one option for hopefully improving the survival rate of patients with this tumor. Transduction of OS cells with the pCMV-IL-12neo plasmid induced a significant increase in IFN-gamma expression by mononuclear cells. This is known to induce antitumor effects mediated by the immune system. In combination with an administration of rIL-18, the IFN-gamma increase was multiplied in a dose-dependent manner. This study demonstrated that osteosarcoma cells can be targeted effectively in vitro by plasmids encoding the IL-12 gene. Considering the synergistic pathways it is reasonable to combine a local, gene transfer based on IL-12 with a rIL-18 administration to trigger the potentially promising immuno-effects for adjuvant treatment of osteosarcomas.</dcterms:abstract>
<dc:creator>Merk, Harry</dc:creator>
<dc:creator>Prisack, Johannes Bernd</dc:creator>
</rdf:Description>
</rdf:RDF>Interner Vermerk
xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter
Prüfungsdatum der Dissertation
Finanzierungsart
Kommentar zur Publikation
Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
